These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11475442)

  • 21. Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study.
    Freedman MS; Francis GS; Sanders EA; Rice GP; O'Connor P; Comi G; Duquette P; Metz L; Murray TJ; Bouchard JP; Abramsky O; Pelletier J; O'Brien F; ;
    Mult Scler; 2005 Feb; 11(1):41-5. PubMed ID: 15732265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.
    Pakdaman H; Abbasi M; Gharagozli K; Ashrafi F; Delavar Kasmaei H; Amini Harandi A
    Neurol Sci; 2018 Dec; 39(12):2107-2113. PubMed ID: 30171370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study.
    Polman C; Barkhof F; Kappos L; Pozzilli C; Sandbrink R; Dahlke F; Jakobs P; Lorenz A;
    Mult Scler; 2003 Aug; 9(4):342-8. PubMed ID: 12926838
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRISMS: the story of a pivotal clinical trial series in multiple sclerosis.
    Cohen BA; Rivera VM
    Curr Med Res Opin; 2010 Apr; 26(4):827-38. PubMed ID: 20121658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon beta and multiple sclerosis: look at the evidence.
    Patti F; Reggio A
    Int J Clin Pract Suppl; 2002 Sep; (131):23-32. PubMed ID: 12564809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing efficacy and side effects of a weekly intramuscular biogeneric/biosimilar interferon beta-1a with Avonex in relapsing remitting multiple sclerosis: a double blind randomized clinical trial.
    Nafissi S; Azimi A; Amini-Harandi A; Salami S; shahkarami MA; Heshmat R
    Clin Neurol Neurosurg; 2012 Sep; 114(7):986-9. PubMed ID: 22429566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
    Li DK; Zhao GJ; Paty DW;
    Neurology; 2001 Jun; 56(11):1505-13. PubMed ID: 11402107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis.
    Saida T; Kira J; Ueno Y; Harada N; Hirakata T
    Mult Scler Relat Disord; 2016 May; 7():102-8. PubMed ID: 27237769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 May; 18(1):68. PubMed ID: 29751787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
    Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b.
    Fitzgerald KC; Munger KL; Köchert K; Arnason BG; Comi G; Cook S; Goodin DS; Filippi M; Hartung HP; Jeffery DR; O'Connor P; Suarez G; Sandbrink R; Kappos L; Pohl C; Ascherio A
    JAMA Neurol; 2015 Dec; 72(12):1458-65. PubMed ID: 26458124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients.
    Rudick RA; Cutter GR; Baier M; Weinstock-Guttman B; Mass MK; Fisher E; Miller DM; Sandrock AW
    Mult Scler; 2005 Dec; 11(6):626-34. PubMed ID: 16323317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of subcutaneous interferon β-1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study.
    De Stefano N; Sormani MP; Stubinski B; Blevins G; Drulovic JS; Issard D; Shotekov P; Gasperini C
    J Neurol Sci; 2012 Jan; 312(1-2):97-101. PubMed ID: 21880336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis.
    Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK
    Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS.
    Wu X; Dastidar P; Kuusisto H; Ukkonen M; Huhtala H; Elovaara I
    Acta Neurol Scand; 2005 Oct; 112(4):242-7. PubMed ID: 16146494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM; Rudick RA; Munschauer FE; Mass MK; Salazar AM; Coats ME; Labutta R; Richert JR; Cohan SL; Genain C; Goodkin D; Toal M; Riester K
    Mult Scler; 2005 Aug; 11(4):409-19. PubMed ID: 16042223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.